Novo Nordisk A/S 2012 AR2
The report highlights Novo Nordisk's financial, social, and environmental performance for the fiscal year 2012. The company achieved strong financial results, with sales increasing by 18% in Danish kroner and net profit growing by 25%. Key clinical milestones included the approval of new-generation insulins Tresiba and Ryzodeg in Japan and the EU. On the sustainability front, the company set a long-term target to reach 40 million patients with diabetes care products by 2020 and reported a 30% increase in CO2 emissions from energy consumption due to production growth.
Company: Novo Nordisk A/S
Sector: Manufacturing
Country: Denmark
Year: 2012
Type: AR2
Pages: 116
Back to company
Novo Nordisk A/S
Annual Report
The report highlights Novo Nordisk's financial, social, and environmental performance for the fiscal year 2012. The company achieved strong financial results, with sales increasing by 18% in Danish kroner and net profit growing by 25%. Key clinical milestones included the approval of new-generation insulins Tresiba and Ryzodeg in Japan and the EU. On the sustainability front, the company set a long-term target to reach 40 million patients with diabetes care products by 2020 and reported a 30% increase in CO2 emissions from energy consumption due to production growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees